LINC02395: A Potential Drug Target and Biomarker (G101927292)

Target Name: LINC02395

NCBI ID: G101927292

LINC02395

Other Name(s): Long intergenic non-protein coding RNA 2395 | long intergenic non-protein coding RNA 2395

LINC02395: A Potential Drug Target and Biomarker

Non-protein-coding RNAs (NPcNs) have emerged as a promising area of research in recent years due to their involvement in various cellular processes. One class of NPcNs, known as long intergenic non-protein coding RNAs (lncNs), have been identified that are different from traditional protein-coding RNAs (pcRNAs) in their structure, function, and regulation. LINC02395 is a well-validated lncN that has been shown to play important roles in various cellular processes, including cell growth, differentiation, and metabolism. Additionally, recent studies have suggested that LINC02395 may also have potential as a drug target or biomarker.

The LINC02395 gene is located on chromosome 16 at position 18.3 kb upstream of the actively transcribed gene APC2. APC2 encodes a protein that is involved in the detoxification of xenobiotics, such as drugs and environmental toxins, which can cause oxidative stress and DNA damage. The LINC02395 gene has a unique feature, known as its intron-exon structure, which is composed of one exon that is predominantly derived from the highly conserved NHEJ gene, and the other exon that is derived from the less conserved GRI-HOMER gene. This unique structure has been implicated in LINC02395's ability to generate a stable RNA molecule with a long half-life, as well as its ability to interact with other RNA molecules.

LINC02395 has been shown to play important roles in various cellular processes, including cell growth, differentiation, and metabolism. For example, studies have shown that LINC02395 is involved in the regulation of cell cycle progression, and that it promotes the G1 phase by increasing the amount of RNA polymerase II (RNA polymerase II) in the cell. Additionally, LINC02395 has been shown to be involved in the regulation of gene expression, and that it can act as a negative regulator of the expression of various genes, including its own gene.

In addition to its role in cellular processes, LINC02395 has also been suggested as a potential drug target or biomarker. The lncN has been shown to interact with various drug molecules, including small molecules, peptides, and proteins, which suggests that it may be a useful target for drug development. Additionally, LINC02395 has been shown to play a role in the regulation of cellular processes that are implicated in various diseases, such as cancer, neurodegenerative diseases, and metabolic disorders. This suggests that it may be a useful biomarker for these diseases.

In conclusion, LINC02395 is a well-validated lncN that has been shown to play important roles in various cellular processes. Its unique intron-exon structure and ability to interact with other RNA molecules make it a promising candidate as a drug target or biomarker. Further research is needed to fully understand the role of LINC02395 in cellular processes and its potential as a drug target or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2395

The "LINC02395 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02395 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets